ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1878

Diagnostic Performance of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis: Results from a Brazilian Validation Cohort

Farley Carvalho1, Cintia Camargo2, Bruna Fernandez1 and Cristiane Kayser2, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: New classification criteria for systemic sclerosis (SSc) were proposed by the ACR/EULAR in 2013, due to the low sensitivity of the 1980 ACR classification criteria for patients with early and limited SSc. This study aimed to evaluate the diagnostic performance of the new ACR/EULAR classification criteria for SSc in clinical practice including patients with early SSc.  

Methods: Data from 178 patients with SSc, including 122 patients with established SSc (according to the 1980 ACR criteria) and 56 with early SSc (according to the LeRoy and Medsger 2001 criteria) were consecutively collected from September 2014 to May 2015 from a tertiary outpatient clinic. Data from 141 control patients with systemic lupus erythematosus, dermato/polymyositis, mixed connective tissue disease, undifferentiated connective tissue disease, Sjögren’s Syndrome, and primary Raynaud’s phenomenon were also collected. The sensitivity and specificity of the old and the new ACR/EULAR criteria were determined in several subgroups of patients with early SSc. The diagnostic performance of each item of the new criteria was also evaluated. The performance of the new ACR/EULAR criteria in discriminating SSc patients from controls was also evaluated by means of the Receiver Operating Characteristic (ROC) curve analysis. The best cut-off was determined based on the Youden’s index criteria.

Results: The new classification criteria showed a sensitivity of 77.6% and a specificity of 98.5% among the 178 patients with established and early SSc, and had a significantly higher sensitivity compared to the 1980 ACR criteria (p<0.001) (Table 1). Sixteen of 56 (28.5%) patients who were classified as patients with early SSc, were newly classified as SSc by the 2013 ACR/EULAR criteria. Sensitivity and specificity showed an excellent performance when only early SSc patients with both abnormal nailfold capillaroscopy and positive SSc-related antibodies were included (sensitivity of 90.0% and specificity of 98.5%) (Table 1). For this sample, the new classification criteria presented high accuracy in diagnosing SSc, with an area under the ROC curve (AUC) of 0.996 (95%CI 0.99-1.00; p<0.001). The best cut-off was a score of ≥8 (sensitivity of 96.1% and specificity of 97.9%). Abnormal nailfold capillaroscopy and sclerodactily were the individual items with the best performance (sensitivity of 93.3% and 78.2%; specificity of 83.6% and 100%, respectively). 

Table 1.Sensitivity and specificity of the 1980 ACR criteria and the 2013 ACR/EULAR criteria in different subsets of patients

                                   ACR 1980                                     ACR/EULAR 2013
       Sensitivity (95% CI) Specificity (95% CI)                Sensitivity (95% CI) Specificity (95% CI)
SSc patients (established and early SSc) (n=178)

68%

(0.60- 0.74)

100%

(0.97- 1.00)

77.6%

(0.71-0.83)

98.5%

(0.94-0.99)

Established SSc and early SSc with abnormal nailfold capillaroscopy

and positive SSc-related antibodies (n=152)

80%

(0.73-0.85)

100%

(0.97-1.00)

90%

(0.85-0.94)

98.5%

(0.94-0.99)

Early SSc (n=56)

0%

(0-0.06)

100%

(0.97-1.00)

28.5%

(0.18-0.41)

98.5%

(0.94-0.99)

  Early SSc subsets

Raynaud’s phenomenon plus abnormal nailfold capillaroscopy

and positive SSc-related antibodies (n=13)

                      –               –

53%

(0.29-0.76)

98.5%

(0.94-0.99)

Raynaud’s phenomenon plus abnormal nailfold capillaroscopy

and negative SSc-related antibodies (n=31)

                      –               –

22%

(0.11-0.39) )

98.5%

(0.94-0.99)

Raynaud’s phenomenon plus normal nailfold capillaroscopy

and positive SSc-related antibodies (n=12)

                      –               –

16%

(0.04-0.44)

98.5%

(0.94-0.99)

Conclusion: The 2013 ACR/EULAR classification criteria for SSc presented higher sensitivity than the 1980 ACR criteria particularly among patients with early SSc. The cut-off of ≥ 8 for total score showed an excellent sensitivity with no loss of the specificity for the classification of patients with SSc in this cohort of patients, and may allow early intervention among patients with early disease.


Disclosure: F. Carvalho, None; C. Camargo, None; B. Fernandez, None; C. Kayser, None.

To cite this abstract in AMA style:

Carvalho F, Camargo C, Fernandez B, Kayser C. Diagnostic Performance of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis: Results from a Brazilian Validation Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/diagnostic-performance-of-the-2013-acreular-classification-criteria-for-systemic-sclerosis-results-from-a-brazilian-validation-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-performance-of-the-2013-acreular-classification-criteria-for-systemic-sclerosis-results-from-a-brazilian-validation-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology